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Chapter 5
The effect of tumour necrosis factor alpha, 
interleukin 6 and interferon alpha on dengue 





Dengue is currently the most prevalent arthropod-borne viral infection world-wide, yet there 
is no licensed vaccine or therapeutic available. Severe disease is associated with high 
expression of tumour necrosis factor alpha (TNFa), and interleukin 6 (IL6). Moreover, type 
I interferons (IFN) have been used in a clinical setting during the Cuban epidemic. Yet, 
little is known about the effect of these cytokines on dengue virus infection and production 
in primary cells. We investigated and characterized the effects of these cytokines on 
primary human macrophages. Both TNFa	 and	 IL6	 did	 not	 have	 significant	 effects	 on	
dengue infection of macrophages, while IFNa	was	antiviral.	The	efficacy	of	IFNa negatively 
correlated	with	the	time	point	of	application	and	the	viral	dose.	Moreover,	its	efficacy	also	
depends on the infecting dengue virus serotype. Taken together, our results provide insights 
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Dengue virus (DENV) is a positive sense single-stranded RNA virus belonging 
to the family Flaviviridae, genus Flavivirus. Currently, DENV is the most common 
arthropod-borne viral infection occurring worldwide1. The virus has four antigenically 
distinct serotypes 2, and infection with any serotype can cause severe disease 
and vascular leakage 3. Although a low proportion of all infections result in severe 
disease 4, 5, the case fatality rate of severe disease can be as high as 15%5. Early 
detection,	fluid	replacement	and	proper	medical	care	can	reduce	the	case	fatality	
rate below 1% 3.
Little is known about the causes of vascular leakage in DENV-infected patients, 
although	genetic	predispositions,	host	immune	status,	as	well	as	virus	fitness	are	
associated with severe disease (reviewed in 6). Studies in mice revealed that high 
virus titres, Tumour necrosis factor alpha (TNFa) production, and macrophage 
(Mf)	infiltration	are	critical	factors	in	dengue-induced	haemorrhage	7. In humans, 
high levels of TNFa and IL6 are associated with severe dengue disease 8-10, and 
subsequent vascular damage 7, 11, 12. This suggests that TNFa and IL6 primarily 
have pathogenic effects in humans, and leaves the question open whether these 
cytokines also have anti-viral effects. However, there is no uniformity with regards 
to the potential pathogenic effects of TNFa in dengue patients 13-15, as well as 
its antiviral effects in cell lines16 or primary cells 17, 18. IL6, however, was found to 
enhance DENV production in dendritic cells 18. In line with this, IL6 suppressed the 
expression of interferon beta (IFNb) by human Mf 19. However, the latter report did 
not quantify the effects of IL6 on DENV infectivity or production by Mf, and this 
remains to be resolved.
In chapter 4, we observed increased gene expression of IL6 and TNFa in Mf 
cultures infected with DENV at a high MOI. Moreover, at these conditions, virus 
production per infected cell was enhanced compared to low-infection conditions. 
Hence, our results suggest that IL6 and/or TNFa expression is triggered by the 
larger viral burden, or that these cytokines are responsible for the large virus 
burden. 
Besides IL6 and TNFa, we also found upregulated expression of type I IFN (a/b) 
in cultures of DENV2-infected Mf (Chapter 4). During the Cuban dengue epidemic, 
the	efficacy	of	type	I	IFN	was	beneficial	to	some	patients	20. However, no further 
human trials were conducted, in part because of the potential side effects of IFN 20. 
Moreover, although type I IFNs are known to possess antiviral effects 16, 21, 22, IFNs 
are also known to sustain infection of viruses as e.g. Lympho choriomeningitis 
virus 23, 24. Also, the potency of type I IFN to regulate DENV infection mostly has 
been evaluated in human monocytes and monocyte-like cells16, 25, yet little is 
known about its potency on human Mf. Hence, we wished to evaluate the effects 
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Results
First,	 we	 investigated	 the	 influence	 of	 TNFa, IFNa, and IL6 on DENV particle 
production in human primary Mf. Human Mf were generated as described in 
chapters 3 and 4 by culturing isolated blood monocytes for 6 days in the presence 
of 100ng/mL M-CSF. At day 6, increasing concentrations of exogenous TNFa, 
IFNa, and IL6 were added to Mf 2h prior to infection with DENV. Human Mf were 
infected with DENV2 s16681 at a multiplicity of infection (MOI) of 5. Virus particle 
production was determined by qRT-PCR 26 at 24h post infection (hpi) for TNFa and 
IL6, or 26hpi for IFNa. While IFNa already reduced virus production at the lowest 
concentration tested (i.e. 1 U/mL; 3.7 pg/mL), neither TNFa	nor	IL6	significantly	
affected virus production up to 105 U/mL (i.e. 2mg/mL of TNFa and 10mg/mL of IL6, 
respectively)(Fig. 1A). 
Also, when TNFa and IL6 were added to Mf at 24h prior to infection, we 
observed no effect on DENV infectivity (Fig. 1B) and infectious virus particle 
production (Fig. A1A). In these experiments, IL4 (25ng/mL, 125U/mL) was used as 
a positive control 27, 28 as IL4 is known to promote infection through upregulation of 
DENV binding factors DC-SIGN and mannose receptor 27, 29. Indeed, IL4 increased 
the number of infected cells (Fig. 1B) and upregulated DC-SIGN expression (Fig. 
A1B). Taken together, these results show that TNFa and IL6 do not possess clear 
pro- or anti-viral effects in Mf. Furthermore, IFNa did reduce DENV production in 
Mf.
Next, we determined if the time point of IFNa	addition	influences	the	efficacy	
of IFNa (Fig. 1C). To this end, 1U/mL of IFNa was added to the cells before, 
during	and	after	infection.	This	approach	also	provides	insight	in	the	efficiency	of	
translation of DENV2 within primary human Mf since the non-structural proteins of 
DENV2 are known to inhibit IFN-signalling pathways 30-33. Based on literature, it is 
expected that IFNa	ceases	to	be	efficacious	when	sufficient	non-structural	proteins	
have been produced within the cell. In Mf, IFNa	proves	 to	be	most	efficacious	
when added prior to infection or concurrently with infection(Fig. 1C). Thereafter, a 
clear MOI-dependent effect can be seen; at MOI 5, the 50%-reduction relative to 
non-treated was reached by 0hpi addition of IFN, whereas at MOI 1 this point was 
reached 8h later. 
These results show that, once infection is established, the production of 
DENV2 in primary Mf is largely resistant to IFNa. To strengthen this notion, we 
investigated the effect of 10 and 50U/mL of IFNa on DENV production when added 
at 10hpi(Fig. 1D). There was little to no effect in terms of virus production. This 
experiment	confirmed	that	established	DENV	infection	is	resistant	to	the	action	of	
IFNa.
Fig. 1: The effects of exogenous IFNa, TNFa, and IL6 on productive DENV2 infection of primary 
human Mf. (A) A range of concentrations of IFNa, TNFa, and IL6 was tested for its effect on productive 
DENV2 infection of primary human Mf. Each cytokine was added at 2h prior to infection at MOI 5. The 
cytokine	 concentration	was	maintained	 throughout	 the	 experiment.	Virus	 production	was	 quantified	
by qRT-PCR at 26hpi (IFNa) or 24hpi (TNFa and IL6). The results of each donor were normalized 
relative to the non-treated condition and depict the SEM of 2 donors (IFNa) or 5 donors (TNFa and 
IL6), each condition in duplicate. (B) TNFa and IL6 (106 U/mL) were added at 24h prior to infection, 
followed	by	infection	with	DENV2	at	MOI	5	(circles)	or	MOI	1	(squares).	Infection	was	quantified	by	flow	
cytometry at 24hpi. Shown are SEM of 3 donors. (C) A time course of IFNa add-on was performed on 
primary human Mf which had been infected at MOI 1 (white bars) or MOI 5 (black bars). The cytokine 
concentration	was	maintained	 throughout	 the	experiment,	and	DENV2	genomes	were	quantified	by	
qRT-PCR	at	26hpi.	Bars	show	SEM	of	≥3	donors,	each	condition	in	duplicate.	(D)	The	IFN-resistance	
of DENV2-infected Mf was tested by adding an increasing amount of IFNa to the Mf at 10hpi. Shown 
is the SEM of 4 donors. (E) The time course in (C) was supplemented with FACS analysis to quantify 
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Furthermore, we questioned if the effect of IFNa on the virus production, as 
seen in Fig. 1C, was due to a lower number of infected cells, or a lower virus 
production per infected cell. Thus, we repeated the IFNa add-on time course with 
MOI	5	and	quantified	the	infected	cell	mass	at	26hpi	by	flow	cytometry	(Fig.	1E).	
Figure 1E shows that IFNa predominantly reduces the number of DENV2-infected 
Mf when it is added prior to infection. When comparing Figure 1C with 1E, it 
becomes apparent that IFNa has a stronger effect on DENV2 production than 
infection, suggesting that IFNa mostly acts on virus replication within the Mf. To 
analyse the effect of IFNa	on	viral	protein	translation,	we	employed	flow	cytometry	
to quantify the relative content of the viral E protein per infected cell based on the 
mean	fluorescence	intensity	(MFI).	The	MFI	correlates	with	the	amount	of	antigen	
within	the	cell	and	therefore	likely	reflects	the	viral	translation.	Strikingly,	while	the	
number of infected cells decreased due to IFNa-addition (Fig. 1D), the MFI of the 
infected cells remained similar to the non-treated condition. For example, addition 
of IFNa at -2hpi decreased the percentage of infected cells with ~45% (Fig. 1D) 
yet the MFI of the infected cells was still 102.3%±1.3 compared to the cells that 
were not treated with IFNa (SEM of 3 donors). This indicates that IFNa does 
not affect viral protein translation in cells with established infection. Therefore, 
we hypothesize that early application of IFNa predominantly prevents infection 
whereas late application of IFNa reduces replication16 but not viral translation. 
Next, we wondered if the effect of IFNa	 on	 DENV2	 is	 serotype-specific.	
Therefore, we tested the effect of 1U/mL of IFNa on the infectivity of DENV3 strain 
H87 and DENV4 strain 1036 (Fig. 2). Mf were pre-activated incubated with 1U/
mL of IFNa for 2h and subsequently infected with one focus-forming unit (FFU) 
per	cell.	Virus	production	was	quantified	at	26hpi	using	both	FFU	assay	(infectious	
virus) and qRT-PCR (total virus). 
Figure 2 shows that IFNa	does	not	significantly	reduce	the	total	virus	production	
of DENV3 and DENV4 in Mf. Yet, for DENV3 and DENV4, however, there was 
a reduction in the number of produced infectious particles. The values of IFNa-
treated infectious DENV3 fell below the limit of detection (10 FFU/mL). It is 
however important to note that we observe a larger reduction in the number of 
infectious DENV2 in the FFU assay than in the PFU assay (~3.5 Log10 reduction 
versus ~1Log10 reduction, respectively). We do not have an explanation for this 
difference, but we hypothesize that residual IFN present in the cell supernatants 
has a more pronounced effect in the FFU assay than in the PFU assay due to the 
cell lines used in these assays; i.e. Vero WHO cells versus BHK21 clone 15. In this 
sense, the reduction of the DENV4 titre is quite modest and might be attributed to 
the	residual	IFN	rather	than	reflecting	a	lower	infectious	virus	production.	
Fig. 2: The serotype-specific effect of IFNa on DENV infection of primary human Mf. Cells were 
pre-activated with 1U/mL of IFNa at 2h prior to infection, followed by infection with one focus-forming 
unit	of	DENV	per	cell.	Virus	production	was	quantified	at	26hpi	by	qRT-PCR	(total	virus	production;	
genome-containing particles (GCPs)) or by immunofocus assay (infectious virus; focus-forming unit 
(FFU)). Shown are SEM of 4 donors, with each condition performed in duplicate.
Discussion
Little is known about the causes of vascular leakage in DENV-infected patients, 
although several cytokines have been found to be associated with haemorrhagic 
fever, including TNFa, and IL6 7-10. While these cytokines are associated with 
disease in humans, little is known about their antiviral or pro-viral effect on the 
level of DENV-infected cells 13. In contrast, more studies have been performed into 
the effects of type I IFN on DENV infectivity 21, 25, yet relatively few studies have 
been done with primary human cells. We tested the effects of TNFa, IL6 and IFNa 
on primary human Mf. 
We found that neither TNFa	nor	IL6	significantly	influenced	DENV	infectivity	or	
production in human Mf. This is in line with the lack of effect of TNFa on cell lines 
16 or human Mf17.	However,	our	findings	for	 IL6	are	 in	contrast	with	 the	modest	
pro-viral effect of IL6 on DENV-infected dendritic cells 18, and the negative effect of 
IL6 on IFNb expression in human Mf 19. However, the latter report did not quantify 
the effects of IL6 on DENV infectivity or production by Mf. We measured this and 
found no pro-viral effect of IL6 on DENV-infection of Mf. Therefore, neither TNFa 
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We found that IFNa possesses antiviral activity on DENV2 infection of primary 
human Mf. While this cytokine was a very potent inhibitor of DENV2 infection 
when added before or concurrent with infection, it is ineffective against established 
DENV2 infection of Mf. Such a time constrain has been noted before in cell lines 16 
and Cuban patients 20. The time-dependent effect has been related to translation 
of the viral genome and subsequent production of viral non-structural proteins. 
The non-structural proteins are known to impair the IFN signalling within the host 
cell 30-33. While we did not quantify the levels of these non-structural proteins, we 
could	quantify	 the	 viral	 translation	on	per-cell	 basis	by	 flow	cytometric	 analysis	
and found that the amount of viral proteins within infected cells is similar between 
treated and non-treated cells. 
Two observations are in line with a correlation between IFNa-insensitivity and 
viral translation; i) infecting Mf at a higher MOI decreased the time frame wherein 
the virus production could be suppressed by IFNa. We already showed in chapter 
4 that cells infected at MOI 5 have higher viral protein content than cells infected 
at MOI 1. Furthermore, established DENV infection proved to be resistant to much 
higher concentrations of IFNa than Mf with de novo infection, possibly since there 
are	 sufficient	 non-structural	 proteins	within	 these	 cells	 to	 interfere	with	 the	 IFN	
signalling. Given that the MFI was similar between treated and non-treated cells 
while the number of infected cells was halved, we hypothesize that IFNa treatment 
limits the success rate of infection but does not affect viral translation. 
Moreover, the results show that the antiviral effect of IFNa is serotype-dependent 
and future research should ascertain if DENV3 and DENV4 are IFNa-resistant and 
whether	the	effect	is	strain	specific	34. Moreover, it should be tested whether the 
low	efficacy	of	IFNa against DENV3 and DENV4 can be overcome by using higher 
concentrations.	Especially	since	it	 is	known	that	the	efficiency	of	translation	and	
replication varies between DENV strains 35.
The work presented in this chapter provides insight in the effects of TNFa, IL6 
and IFNa on DENV infectivity and production by primary human Mf. Only IFNa has 
therapeutic value for the treatment of DENV-infection in Mf, yet the use of IFNa is 
predominantly limited to pre-infection. In contrast, IFNg	appears	to	be	efficacious	
against both de novo and established DENV infection 36, 37 and more research is 
needed	to	evaluate	its	efficacy	against	DENV	infection	of	primary	human	cells.
Acknowledgement 
The authors thank Silvia Rattigan for her technical assistance.
Materials and methods
Primary cells originated from buffy coats derived from blood donors who gave 
informed consent as per declaration of Helsinki. Monocytes were isolated through 
gelatin-adherance 26 and subsequently differentiated into macrophages, as 
described afore in chapters 3 and 4. 
Cytokines were purchased from Prospec-Tany (Rhehovoth, Israel), all were 
recombinant human cytokines: Macrophage colony stimulatory factor (M-CSF, 
5∙105 U/mg), interleukin 4 (IL4; 5∙106 U/mg), IL6 (1∙107 U/mg), Interferon alpha 2a 
(IFNa2a; 2.7∙108 U/mg), and Tumor Necrosis Factor alpha (TNFa, 5∙107 U/mg).
Virus stocks of dengue virus were propagated on C6/36 cell line, as described 
previously25, 37.	Clarified	supernatants	were	used	in	the	experiments.	The	specific	
infectivity of the stocks in this manuscript were: 78.8 genome-containing particles 
per plaque forming unit (dengue virus 2 strain 16681), 2100 genome-containing 
particles per focus forming unit (dengue virus 3 strain H87), and 700 genome-
containing particles per focus forming unit (dengue 4 strain 1036). 
Virus quantitation of total virus particles was performed as described before by 
qRT-PCR 25,	with	minor	modifications	as	described	in	chapter	3.	For	DENV2,	the	
infectious virus titre was determined by plaque assay on BHK-21 clone 15 (Kind gift 
of Richard Kuhn, Purdue University) as described previously 25	with	a	modification:	
cells	 were	 plated	 on	 24-wells	 plates	 and	 titres	 were	 quantified	 at	 5	 days	 post	
infecton. For DENV2,3,4, the infectious titre was determined by immunofocus 
assay on Vero WHO cells as described previously 38.
Flow cytometry was performed as described previously 39 using either the 
flavivirus-crossreactive	 antibody	 4G2	 or	 the	 DENV2-specific	 antibody	 3H5	
(Millipore, UK) as primary antibody and donkey anti-mouse IgG coupled to AF647 
(Molecular Probes). DC-SIGN expression was detected using mouse anti-human 
DC-SIGN as primary antibody and PE-labelled anti-murine IgG as secondary 
antibody (both purchased from R&D systems).
Add-on experiments, to test the effect of a cytokine by addition to the cells, 
were performed by preparing stock solutions of the cytokines at 10-fold higher 
concentrations. At the designated time point, 10% of the culture volume was 
removed and replaced with the same volume of the stock. Cytokine concentrations 
were subsequently maintained throughout the experiment, except for IL4 which 
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Supplemental materials
Fig. A1: The effect of a prolonged incubation with IL4, IL6, and TNFa on productive 
DENV infection in Mf. 
(A) Productive DENV2 production by human Mf infected after 24 – 48h pre-incubation 
with IL4, IL6 or TNFa. The former at a concentration of 125U/mL, and the latter two at the 
concentration of 106 U/mL. Infectious virus titres were determined at 24hpi by plaque assay 
on BHK-21, clone 15 cells. Dashed line represents the limit of detection of the plaque assay. 
Shown are SEM of 3 donors. (B) Pre-incubating Mf for 48h prior to infection with IL4 (25ng/
mL; 125U/mL) enhanced expression of the DENV binding factor DC-SIGN expression on 
the surface of Mf. (Figure courtesy Flipse, J. & Rattigan, S.)
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